Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBT Margin (2016 - 2025)

Historic EBT Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 135.69%.

  • Spero Therapeutics' EBT Margin fell 64200.0% to 135.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 107.65%, marking a year-over-year decrease of 1147600.0%. This contributed to the annual value of 143.04% for FY2024, which is 1713100.0% down from last year.
  • As of Q3 2025, Spero Therapeutics' EBT Margin stood at 135.69%, which was down 64200.0% from 12.01% recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' EBT Margin registered a high of 212.54% during Q4 2022, and its lowest value of 1456.5% during Q1 2022.
  • In the last 5 years, Spero Therapeutics' EBT Margin had a median value of 236.07% in 2025 and averaged 392.18%.
  • Data for Spero Therapeutics' EBT Margin shows a peak YoY increase of 12120300bps (in 2022) and a maximum YoY decrease of -11920500bps (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Spero Therapeutics' EBT Margin stood at 999.49% in 2021, then surged by 121bps to 212.54% in 2022, then plummeted by -64bps to 75.48% in 2023, then crashed by -282bps to 137.58% in 2024, then grew by 1bps to 135.69% in 2025.
  • Its EBT Margin stands at 135.69% for Q3 2025, versus 12.01% for Q2 2025 and 236.07% for Q1 2025.